Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Senaparib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Senaparib is a once-a-day maintenance capsule for advanced ovarian cancer, developed in China by IMPACT Therapeutics and sold there as 派舒宁®. It is taken after chemotherapy has worked, to help keep the cancer from coming back.
China's National Medical Products Administration (NMPA) approved it on 16 January 2025, as a single medicine, for adults with:
It is a prescription cancer medicine and should only be used under a gynaecologic or medical oncologist.
Cells constantly repair small breaks in their DNA, and two enzymes called PARP1 and PARP2 are part of that repair crew. Senaparib is a PARP inhibitor: it blocks these enzymes, so damage builds up inside the cancer cell until it can no longer survive. Ovarian cancer cells often already have weak DNA repair, for example because of a BRCA mutation, which makes them especially sensitive to this effect. In the main trial, it also helped women without a BRCA mutation.
The phase 3 FLAMES trial, published in Nature Medicine in 2024, included 404 women in China with newly diagnosed stage III–IV ovarian cancer that had responded to platinum chemotherapy. They took senaparib (271 women) or a placebo (133) for up to two years.
The capsules used in the trials contain 10 mg each, so the usual 100 mg dose is ten capsules once a day. Your oncologist will set the exact dose from the Chinese prescribing information.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Blood counts: the main side effects are on the blood. In FLAMES, anaemia affected 81% of women on senaparib, low neutrophils 76%, low white cells 75% and low platelets 70%. Blood counts are checked regularly, especially in the first months, and the dose can be paused or lowered. Report unusual tiredness, breathlessness, bruising, bleeding or fever.
Overall: severe (grade 3 or higher) side effects occurred in 66.3% of women on senaparib and 20.3% on placebo, mostly from low blood counts. No side effect led to death in the trial.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The capsules can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval and is not sold in Indian pharmacies. The US FDA has not approved it. In Europe, the EMA's medicines committee gave a positive opinion in September 2026 under the name Sepalna, but a final European approval has not yet been issued.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For another option in ovarian cancer, see our page on Elahere.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Because the usual dose is ten capsules a day, and the dose may be lowered along the way, we work out the monthly quantity from the latest prescription. The capsules travel in their sealed original packs under temperature-controlled shipping and should be stored as directed on the pack. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating hospital on a valid oncologist's prescription.
Gynaecologic oncology teams in Delhi see women from across North India, and our New Delhi dispatch point keeps delivery times short.
Oncologists in Mumbai can request the capsules once first-line chemotherapy has finished and the response is confirmed.
Each month's supply can be delivered to the patient at home or to the hospital pharmacy.
A major centre for ovarian cancer care in South India, used to importing medicines for individual patients.
We adjust each order to the current dose, so a dose change does not leave the patient short.
Patients in Kolkata and the eastern states can follow the same documented import route, with updates at each step.
The treating oncologist can send the prescription and chemotherapy response report to start the process.
Oncologists in Ahmedabad can arrange maintenance supply for women who have just completed platinum chemotherapy.
Patients in Rajasthan can receive their capsules without travelling, as long as the import is in their name.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating hospital.
We arrange regular deliveries for women treated at cancer hospitals across Uttar Pradesh.
Patients across Kerala can have their monthly supply delivered to Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
